Genus PLC
LSE:GNS
Genus PLC
LSE:GNS
Price:
2 490
GBX
-1.39%
Market Closed
Market Cap:
£1.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Genus PLC
LSE:GNS
|
UK |
|
John Menzies PLC
LSE:MNZS
|
UK |
|
Hanmi Pharm Co Ltd
KRX:128940
|
KR |
|
Kunlun Energy Company Ltd
HKEX:135
|
HK |
|
Inspire Medical Systems Inc
NYSE:INSP
|
US |
|
Residential Secure Income PLC
LSE:RESI
|
UK |
|
Scatec ASA
OSE:SCATC
|
NO |
|
M
|
MS International PLC
LSE:MSI
|
UK |
|
Access-Power & Co Inc
OTC:ACCR
|
US |
|
H
|
Hybrid Financial Services Ltd
BSE:500262
|
IN |
|
AbraSilver Resource Corp
XTSX:ABRA
|
CA |
|
Caisse Regionale de Credit Agricole Mutuel Brie Picardie
PAR:CRBP2
|
FR |
|
Roblon A/S
CSE:RBLN B
|
DK |
|
NWF Group PLC
LSE:NWF
|
UK |
|
Airtac International Group
TWSE:1590
|
CN |
|
Great Eastern Holdings Ltd
OTC:GEHDF
|
SG |
|
M
|
Manulife US Real Estate Investment Trust
SGX:BTOU
|
SG |
Multiples-Based Value
The Multiples-Based Value of one
GNS
stock under the Base Case scenario is
hidden
GBX.
Compared to the current market price of 2 490 GBX,
Genus PLC
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GNS Multiples-Based Value
LOCKED
Multiples Across Competitors
GNS Competitors Multiples
Genus PLC Competitors
Genus PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Genus PLC
LSE:GNS
|
1.7B GBP | 2.5 | 34.9 | 14.6 | 22.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.1 | 88.4 | 14.7 | 20.4 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.4B USD | 109.4 | -1 708.3 | 15 870 | -1 791.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.7 | 19.6 | 12.3 | 15.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.2 | 27.8 | 20.9 | 21.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.2 | 35.1 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
